Clinical Trials

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer


Study ID
EMD Serono Research & Development MS201943-0029

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number
Pro2018-0806

Principle Investigator
Dr. Donna McNamara

Phase
II

Sponsor
EMD Serono Research & Development Institute, Inc.


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now